康诺亚-B(02162)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02162 康诺亚-B

未开盘 08-19 16:08:48

77.050

-1.000

-1.28%

最高79.750	最低76.450	成交量122.48万
今开78.100	昨收78.050	日振幅4.23%
总市值230.38亿	流通市值230.38亿	总股本2.99亿
成交额9,469万	换手率0.41%	流通股本2.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02162","market":"HK","secType":"STK","nameCN":"康诺亚-B","latestPrice":77.05,"timestamp":1787126928004,"preClose":78.05,"halted":0,"volume":1224849,"delay":0,"changeRate":-0.012812299807815503,"floatShares":299000000,"shares":299000000,"eps":-2.2249136687262805,"marketStatus":"未开盘","change":-1,"latestTime":"08-19 16:08:48","open":78.1,"high":79.75,"low":76.45,"amount":94685952,"amplitude":0.042281,"askPrice":77.05,"askSize":500,"bidPrice":77,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-2.256365327917699,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787189400000},"marketStatusCode":0,"adr":0,"listingDate":1625673600000,"exchange":"SEHK","adjPreClose":78.05,"openAndCloseTimeList":[[1787103000000,1787112000000],[1787115600000,1787126400000]],"volumeRatio":0.818991087121012,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02162","defaultTab":"news","newsList":[{"id":"1105757298","title":"康诺亚-B（02162）拟申请科创板发行人民币股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1105757298","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105757298?lang=zh_cn&edition=full","pubTime":"2026-08-19 21:43","pubTimestamp":1787147019,"startTime":"0","endTime":"0","summary":"康诺亚生物医药科技有限公司8月19日公告称，其董事会已于2026年8月19日审议通过公司拟发行人民币普通股并在上海证券交易所科创板上市的初步方案。此次发行及上市计划仍需满足多项前提条件，包括但不限于后续董事会审议通过、公司股东大会批准以及取得相关监管部门核准。公司表示，截至公告披露日，除上述初步方案及公告所载信息外，董事会暂未就本次发行向任何监管机构递交申请，也未作出其他安排。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660387426","title":"康诺亚-B(02162)：建议发行人民币股份及于上海证券交易所科创板上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2660387426","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660387426?lang=zh_cn&edition=full","pubTime":"2026-08-19 21:38","pubTimestamp":1787146683,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康诺亚-B(02162)发布公告，于2026年8月19日，本公司董事会议决本公司建议发行于上海证券交易所科创板(科创板)上市并以人民币买卖的普通股(建议发行人民币股份)。建议发行人民币股份须受限于及取决于(其中包括)市况、董事会进一步批准、本公司股东于本公司股东大会批准及取得必要监管批准。截至本公告日期，除建议发行人民币股份的初步方案及本公告另行披露的资料外，董事会并无有关建议发行人民币股份的任何其他计划，亦未就建议发行人民币股份向相关监管机构提出任何申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482247.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","IPOS","BK1574","BK1583","UCmain","KSTR","BK1161","CNHmain","02162","CYB","MUCmain","MCNHmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123477399","title":"康诺亚-B：截至2026年8月19日尚未向监管机构提交人民币股份发行申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1123477399","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123477399?lang=zh_cn&edition=full","pubTime":"2026-08-19 21:33","pubTimestamp":1787146394,"startTime":"0","endTime":"0","summary":"康诺亚-B（KeyMed Biosciences）于2026年8月19日发布公告，明确表示截至目前，公司尚未就人民币股份发行事宜向任何监管机构递交申请。这一消息在市场上引发关注，投资者对该公司潜在的境内融资计划时间表保持观望。康诺亚-B方面强调，相关事项仍处于早期筹划阶段，后续进展将视市场环境及监管要求审慎推进。此举被部分分析人士解读为公司在资本运作节奏上的谨慎态度，或为等待更佳的市场窗口期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02162","BK1587","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104570352","title":"康诺亚-B（02162）2026年上半年营收6.17亿元 海外BD与产品放量助推净赚12.18亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1104570352","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104570352?lang=zh_cn&edition=full","pubTime":"2026-08-19 21:26","pubTimestamp":1787145972,"startTime":"0","endTime":"0","summary":"2026年8月19日，康诺亚生物医药科技有限公司公布截至2026年6月30日止六个月未经审计中期业绩。得益于海外商业拓展及核心产品康悦达放量，公司实现净利润12.18亿元，同比扭亏。成本及费用方面，研发投入3.39亿元，同比下降6%；行政开支0.86亿元，同比下降4%；销售及分销开支2.18亿元，同比增加80%，与康悦达销售增长相对应。其他收入及收益17.06亿元，去年同期为0.76亿元，本期主要包含处置Ouro Medicines股权取得的16.8亿元税前收益。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658695450","title":"康诺亚：差异化管线领跑双赛道 源头创新打开价值空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2658695450","media":"经济参考报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658695450?lang=zh_cn&edition=full","pubTime":"2026-08-11 04:17","pubTimestamp":1786393075,"startTime":"0","endTime":"0","summary":"“成都的产业生态为康诺亚的成长提供了系统性支撑，不仅体现在物理空间的快速成熟，更在于全生命周期的精准赋能。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837005020.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837005020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","02162","BK1587","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658605178","title":"康诺亚-B(02162)：CM512(TSLP x IL-13双抗)注射液用于慢性鼻窦炎伴鼻息肉患者的II期临床试验达到所有研究终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2658605178","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658605178?lang=zh_cn&edition=full","pubTime":"2026-08-10 08:09","pubTimestamp":1786320562,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康诺亚-B 发布公告，公司自主研发的1类新药CM512注射液治疗慢性鼻窦炎伴鼻息肉的II期临床研究已完成数据揭盲及初步统计分析。结果显示：1、CM512达到了全部研究终点，各剂量组疗效表现相当。CM512快速起效，给药第4周即可快速缩小鼻息肉同时显著改善鼻塞，并促进嗅觉功能恢复。基于此II期结果，公司正在快速启动CM512注射液治疗CRSwNP的临床III期研究，并明确300mg，半年给药一次为用药方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477751.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MDTX","BK1574","IBBJ","ENTL","02162","PSYK","BK1161","BK1587","IBBQ","BK1583","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162279464","title":"康诺亚-B（02162）拟于2026年8月19日召开董事会审议中期业绩及派息计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1162279464","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162279464?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:37","pubTimestamp":1786091830,"startTime":"0","endTime":"0","summary":"康诺亚生物医药科技有限公司（股票代码：02162）8月7日公告，公司董事会将于2026年8月19日（星期三）召开会议，审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布事宜，并同时考虑是否派发中期股息（如有）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168283866","title":"异动解读｜康诺亚-B盘中上涨5.46%，多家机构密集增持叠加核心管线利好持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1168283866","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168283866?lang=zh_cn&edition=full","pubTime":"2026-08-07 11:31","pubTimestamp":1786073467,"startTime":"0","endTime":"0","summary":"8月7日，康诺亚-B盘中上涨5.46%，报81.15港元，成交额6363.95万港元。消息面上，近期多家机构密集增持该股。8月6日披露数据显示，东方证券于7月30日增持康诺亚-B约20.35万股，每股均价72.88港元，持股比例由4.98%升至5.05%，触及举牌线。此前高盛亦于7月13日增持28.75万股，持股比例升至5.00%。机构增持与管线利好形成共振，推动股价走强。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"康诺亚-B盘中上涨5.46%，多家机构密集增持叠加核心管线利好持续发酵","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657335496","title":"东方证券股份有限公司(DFZQ)增持康诺亚-B(02162)20.35万股 每股作价约72.88港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657335496","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657335496?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:20","pubTimestamp":1786015229,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，7月30日，东方证券股份有限公司(DFZQ)增持康诺亚-B(02162)20.35万股，每股作价72.8753港元，总金额约为1483.01万港元。增持后最新持股数目为1509.6万股，最新持股比例为5.05%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1476902.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1147","BK1161","BK1574","BK0012","BK0183","02162","BK1583","BK0276","BK1564","BK0028","03958","BK1587","600958","BK0188","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114589336","title":"康诺亚-B：东方证券增持，好仓比例升至5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=1114589336","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114589336?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:11","pubTimestamp":1786007505,"startTime":"0","endTime":"0","summary":"东方证券于2026年7月30日以每股均价72.8753港元买入康诺亚-B（02162）股份20.35万股，涉资约1483.01万港元。东方证券此次增持前持有康诺亚-B好仓1489.25万股，占比4.98%；增持后持股量为1509.60万股，好仓比例升至5.05%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656558525","title":"汇添富基金管理股份有限公司增持康诺亚-B(02162)20.35万股 每股作价约72.88港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2656558525","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656558525?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:19","pubTimestamp":1785842359,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，7月30日，汇添富基金管理股份有限公司增持康诺亚-B(02162)20.35万股，每股作价72.8753港元，总金额约为1483.01万港元。增持后最新持股数目为1509.60万股，最新持股比例为5.05%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475890.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1587","BK1574","BK1583","02162","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196771120","title":"康诺亚-B更新2026年7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1196771120","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196771120?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:58","pubTimestamp":1785747526,"startTime":"0","endTime":"0","summary":"康诺亚生物医药科技有限公司于2026年8月3日披露了截至2026年7月31日的证券变动月报。报告显示，公司法定股本与已发行股本在本月内均保持不变。根据公告，康诺亚-B的法定注册股本总额为500,000,000股，面值为每股USD 0.0001，对应注册股本为USD 50,000。本月末已发行股份数量为298,735,566股，与上月底的298,735,566股一致，库藏股余额为0股。康诺亚-B确认其公众持股量符合香港联交所《上市规则》关于最低公众持股量的要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177158967","title":"异动解读｜康诺亚-B盘中下跌5.38%，CMG901三期临床利好兑现后续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1177158967","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177158967?lang=zh_cn&edition=full","pubTime":"2026-07-29 09:49","pubTimestamp":1785289768,"startTime":"0","endTime":"0","summary":"7月29日，康诺亚-B盘中下跌5.38%，报73.85港元，成交额5157.56万港元，延续前一交易日跌势。消息面上，公司此前公告其与阿斯利康合作开发的靶向CLDN18.2抗体偶联药物CMG901全球III期临床试验CLARITY-Gastric01取得积极顶线结果，在二线及后线CLDN18.2阳性晚期胃癌患者中实现具有统计学显著性的总生存期改善。公司预计该药峰值年销售额达30亿至50亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"康诺亚-B盘中下跌5.38%，CMG901三期临床利好兑现后续承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171373336","title":"异动解读｜康诺亚-B盘中下跌5.59%，CMG901胃癌III期临床达主要终点后利好兑现承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1171373336","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171373336?lang=zh_cn&edition=full","pubTime":"2026-07-28 15:48","pubTimestamp":1785224930,"startTime":"0","endTime":"0","summary":"7月28日，康诺亚-B盘中下跌5.59%，报77.7港元，成交额4.76亿港元。消息面上，公司当日公告其与阿斯利康合作开发的靶向CLDN18.2抗体偶联药物CMG901全球III期临床试验CLARITY-Gastric01取得积极顶线结果。试验显示，CMG901在二线及后线CLDN18.2阳性晚期胃癌患者中，较研究者选择的治疗方案实现了具有统计学显著性的总生存期改善，安全特征与既往研究一致，未发现新安全信号。尽管临床数据积极，股价呈现典型的利好兑现回落走势，市场或已提前定价该预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"康诺亚-B盘中下跌5.59%，CMG901胃癌III期临床达主要终点后利好兑现承压","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654078357","title":"康诺亚-B(02162.HK)：CMG901(AZD0901)全球III期临床试验CLARITY-Gastric01取得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2654078357","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654078357?lang=zh_cn&edition=full","pubTime":"2026-07-28 12:10","pubTimestamp":1785211808,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02162","BK1574","BK1587","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169774882","title":"康诺亚-B：CMG901 全球Ⅲ期试验获积极顶线结果 显著改善晚期胃癌患者总生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1169774882","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169774882?lang=zh_cn&edition=full","pubTime":"2026-07-28 12:05","pubTimestamp":1785211553,"startTime":"0","endTime":"0","summary":"2026年7月28日，康诺亚生物医药科技有限公司公告，其与 AstraZeneca AB 合作开发的靶向 CLDN18.2 抗体偶联药物CMG901在全球Ⅲ期临床试验 CLARITY-Gastric01 中取得积极顶线结果。公告显示，与研究者选择的治疗方案相比，CMG901 在二线及后线 CLDN18.2 阳性晚期胃癌患者中实现了具有统计学显著性且临床意义显著的总生存期改善。安全性评估显示，CMG901 耐受性良好，安全特征与既往研究一致，未发现新的安全信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168368121","title":"康诺亚-B：晚期胃癌临床试验达成总生存期双重主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1168368121","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168368121?lang=zh_cn&edition=full","pubTime":"2026-07-28 12:01","pubTimestamp":1785211269,"startTime":"0","endTime":"0","summary":"康诺亚-B（KEYMED BIO-B）宣布，其针对晚期胃癌的临床试验，已成功达成总生存期的双重主要终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1587","02162","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654458022","title":"【券商聚焦】交银国际：下半年医药板块有望迎来修复 但内部分化或持续加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2654458022","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654458022?lang=zh_cn&edition=full","pubTime":"2026-07-28 10:01","pubTimestamp":1785204072,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，近一个月恒生医疗保健指数涨17.4%，跑赢大市。其中，生物药、CXO及处方药板块表现较优于其他板块。机构持仓方面，2026年年中以来，内资持仓延续提升态势，而外资则略有降低。该机构指，中报季临近，7月以来多家公司业绩预告陆续发布，CXO板块表现亮眼，业绩和订单延续高增长态势。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986903","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","00013","LU1880383366.USD","09996","KURE","03759","01548","LU2328871848.SGD","01093","01801","06078","LU0417516571.SGD","LU2097828714.EUR","03329","02268","LU2039709279.SGD","02269","01276","01177","LU0856984785.SGD","09939","02273","KCE","06160","BK1521","06990","09926","LU0634319403.HKD","06821","LU2476274308.USD","LU1813983027.USD","159938","02096","02596","03692","LU0572944931.SGD","BK1587","HK0000320223.HKD","01951","LU0348783233.USD","LU2399975544.HKD","09966","LU1720050803.USD","01952","06996","LU0588546209.SGD","LU0196878994.USD","01530","HK0000165453.HKD","BK1219"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653145787","title":"康诺亚：重点研发产品CM512拿下突破性治疗认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2653145787","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653145787?lang=zh_cn&edition=full","pubTime":"2026-07-23 14:46","pubTimestamp":1784789160,"startTime":"0","endTime":"0","summary":"7月23日，康诺亚（02162）发布公告，公司重点研发产品CM512（TSLP/IL-13双抗）已被国家药品监督管理局药品审评中心纳入突破性治疗品种名单，用于治疗慢性鼻窦炎伴鼻息肉。CM512是公司自主研发的一种重组抗胸腺基质淋巴细胞生成素（TSLP）和抗白介素-13（IL-13）双特异性抗体，为全球首款IgG-like长效型TSLPxIL-13双阻断剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607233818860096.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607233818860096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1587","BK1161","BK1574","BK1583","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653671165","title":"港股异动 | 康诺亚-B(02162)涨超3% CM512已被国家药品监督管理局药品审评中心纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2653671165","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653671165?lang=zh_cn&edition=full","pubTime":"2026-07-23 14:15","pubTimestamp":1784787355,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康诺亚-B涨超3%，截至发稿，涨2.03%，报85.3港元，成交额8513.19万港元。消息面上，7月23日午间，康诺亚-B发布公告，公司的重点研发产品CM512已被国家药品监督管理局药品审评中心纳入突破性治疗品种名单，用于治疗慢性鼻窦炎伴鼻息肉。截至本公告日期，一项评价CM512注射液在CRSwNP受试者中的安全性和有效性的随机、双盲、安慰剂平行对照II期临床研究正在进行中，试验结果将适时作出公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK4588","VXUS","BK1587","BK1161","BK1574","BK4585","KCAI","02162"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0464},{"period":"1month","weight":-0.1164},{"period":"3month","weight":0.2124},{"period":"6month","weight":0.4177},{"period":"1year","weight":0.0308},{"period":"ytd","weight":0.4415}],"compareEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0043},{"period":"6month","weight":-0.0348},{"period":"1year","weight":0.0148},{"period":"ytd","weight":-0.0053}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康诺亚生物医药科技有限公司是一家生物科技公司，专注于自主发现及开发自体免疫及肿瘤治疗领域的创新生物疗法的公司。该公司还专注于医药产品的研究和开发。该公司的主要产品有CM310、CM326、CM313和CM383，可治疗各种成人、青少年及儿童I型免疫性疾病，例如中重度特应性皮炎、中重度哮喘、慢性鼻賨炎伴鼻息肉、过敏性鼻炎，亦可能可以治疗慢性阻塞性肺疾病。该公司还建立了涵盖生物药开发的关键功能的全面一体化平台。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.062159},{"month":2,"riseRate":0.6,"avgChangeRate":0.057033},{"month":3,"riseRate":0.4,"avgChangeRate":0.01927},{"month":4,"riseRate":1,"avgChangeRate":0.079263},{"month":5,"riseRate":0.2,"avgChangeRate":-0.114444},{"month":6,"riseRate":1,"avgChangeRate":0.128513},{"month":7,"riseRate":0.6,"avgChangeRate":0.112367},{"month":8,"riseRate":0.666667,"avgChangeRate":0.040703},{"month":9,"riseRate":0.8,"avgChangeRate":0.042936},{"month":10,"riseRate":0.4,"avgChangeRate":0.003137},{"month":11,"riseRate":0.6,"avgChangeRate":0.04569},{"month":12,"riseRate":0.2,"avgChangeRate":-0.144855}],"exchange":"SEHK","name":"康诺亚-B","nameEN":"KEYMED BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康诺亚-B(02162)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康诺亚-B(02162)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康诺亚-B,02162,康诺亚-B股票,康诺亚-B股票老虎,康诺亚-B股票老虎国际,康诺亚-B行情,康诺亚-B股票行情,康诺亚-B股价,康诺亚-B股市,康诺亚-B股票价格,康诺亚-B股票交易,康诺亚-B股票购买,康诺亚-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康诺亚-B(02162)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康诺亚-B(02162)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}